DDIT3 and neoplasm: Compared to CHOP (used at standard doses), KPT-276 (75 and 150 mg/kg) and KPT-251 (25 and 50 mg/kg) showed similar or enhanced anti-tumor potential against WSU-DLCL2 xenograft (Fig. 5A).